

behind every great company  
lies an abundance of great life stories



## WORLDWIDE ACKNOWLEDGEMENT FOR THE GREEK PHARMACEUTICAL COMPANY: ELPEN

### How many Greek companies can actually claim that they care for People so convincingly as ELPEN?

In May of 2011, our company's product **Rolenium®** (fluticasone + salmeterol combination therapy) administered by means of our novel, patent-protected inhalation device **ELPENHALER®**, a product of research and development undertaken by the Chairman and Founder of ELPEN, the inventor of the device, received a market authorization for use in patients with asthma and COPD, in seven European countries (Sweden, Germany, Hungary, Slovakia, the Czech Republic, Portugal, and Italy), through the European Decentralized procedure (DCP), with Sweden being designated as the reference member state.

Furthermore, Rolenium® has already been approved in **Greece, Cyprus and Malta through the National Procedure and in each of these countries where the product is already in marketed.**

ELPEN is the first ever pharmaceutical company, worldwide, to be granted an approval for the marketing of a generic, standard dosage combination product for pulmonary administration.

It is noteworthy to add that the pulmonary system is an extremely fragile and difficult pharmaceutical drug target, thus making it extremely difficult to obtain a marketing authorization. For this fact alone, ELPEN is an acknowledged pioneer pharmaceutical company, distinguished both on a local and international level.

The approval of Rolenium® in European markets will surely enhance the company's export endeavors for ELPEN, the largest absolutely Greek pharmaceutical company, a company that is without doubt an added value for the Greek economy.

Today, the **ELPEN Group employs 720 people** (striving to maintain a steady number of job positions without making any cutbacks), with an annual turnover of 170 million Euros (2010), it **ranks in the 7<sup>th</sup> position** among the 300 most important pharmaceutical companies in Greece, and ranks 1<sup>st</sup> with a huge difference, among the absolutely Greek pharmaceutical companies in the country.

Located in Pikermi-Attiki on privately owned land covering an area of 10.000m<sup>2</sup>, it features a state-of-the-art manufacturing facility specializing in the research and development, manufacture, distribution and promotion of pharmaceutical products.

ELPEN was recently awarded the **"Diamond" award** (Most Admired Enterprises 2011) from **STATBANK**, and from the ICAP Group, the **"True Leader 2010" award of the Greek Pharmaceutical Industry.**

Noteworthy is the fact, that **Sir Magdi Yacoub** publicly praised ELPEN for its substantial achievements, expressing a profound admiration for ELPEN's Experimental Research Center calling it a "fantastic and novel project". (The same Laboratory was distinguished in 2005 by the Athens Chamber of Commerce with the "Research and Technological Development" award.)

ELPEN is a fundamentally Greek company, enjoying throughout the decades an outstanding business growth both in Greece and in many countries worldwide, never diverting from its sole purpose and objective: to care for People.

